Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anti-venom Market- Insights
Anti-venom is a medicine used in the treatment of bite from venomous animals including snake, scorpion, spider, jellyfish, stone fish and others. Anti-venoms are sub-categorized in two types: monovalent and polyvalent. According to World Health Organization (WHO), monovalent anti-venoms, also known as monospecific anti-venom, are the anti-venoms that are limited in use to a single species of venomous snake or to a few closely related species, whose venoms show clinically effective cross-neutralization with anti-venom. Polyvalent are anti-venoms that are obtained by fractionating the plasma from animals immunized by a mixture of venoms from several species of venomous snakes
Robust pipeline and frequent approval of novel anti-venom is expected to drive growth of the global anti-venom market
University of Arizona is developing polyvalent F(ab)2 Equine, an anti-venom indicated for the treatment against the North American coral snake (Micrurus) bite. Currently (2018), the product is under phase 3 clinical trial and is expected to get approval in the near future. Presence of such new products in pipeline is expected to support the global anti-venom market growth over forecast period.
Approvals and launches of novel drugs in key regions are also expected to be a major factor to drive anti-venom market growth during the forecast period. For instance, in October 2018, Silanes Laboratories received the U.S. Food and Drug Administration (FDA) approval for Anavip, an anti-venom against the bite of snakes of the Crotalus family, which includes the rattlesnake. In 2017, Rare Disease Therapeutics, Inc. partner of Silanes Laboratories, launched Anavip in the U.S. market.
Furthermore, key players in the market are focusing on increasing shelf life and extending the expiry date of its products. For instance, in September 2018, BTG plc. announced that the U.S. Food & Drug Administration (FDA) has granted approval for updating the shelf life of CroFab Crotalidae Polyvalent Immune Fab (Ovine) to 60 months.
In 2018, Pfizer, Inc. worked with the U.S. Food and Drug Administration (FDA), to extend the expiration date of Antivenin’s Lot No. L67530 for an additional 12 months.
The global anti-venom market size was valued at US$ 504.9 Mn in 2018, and is expected to witness a CAGR of 4.7% during the forecast period (2018 – 2026).
Figure 1. Global Anti-venom Market Share (%), By Animal Type
Source: Coherent Market Insights Analysis (2019)
Asia Pacific is expected to hold dominant position in the global anti-venom market owing to high incidence of snake bites
Asia Pacific anti-venom market is expected to hold the largest market share during the forecast period, owing to high incidence of snake bites in countries such as India and Bangladesh. For instance, according to the data published by Journal of the Association of Physicians of India, in 2017, around 50,000 people die in India annually, due to venomous snake bites.
However, in rural areas of key regions such as India, Bangladesh, and Nepal the adoption rate of anti-venom is quite low as people in these areas adopt traditional treatment outside healthcare facilities over anti-venom. For instance, according to the data published by Journal of Pharmacology & Clinical Toxicology, in June 2018, in Bangladesh only 3% of snake bite victims visit hospital for their treatment
Figure 2. Global Anti-venom Market Share (%) Analysis, By Region, 2026
Source: Coherent Market Insights Analysis (2019)
Various companies, regulatory bodies, and private organizations are working together in order to spread awareness regarding poisonous animal bite and use of anti-venom’s against it. Hence, key players in the market can strategically collaborate with organizations and can work to spread awareness regarding snake bite treatment. For instance, in November 2015, the Health Action International (HAI) and Global Snakebite Initiatives (GSI) partnership took initiative to promote a Member State side-event on snakebite at the World Health Assembly in May 2016, aiming to raise awareness of the global snakebite burden, amplify existing, but underused health systems and scientific innovations.
High price of anti-venom and treatment procedure with anti-venoms are expected to be the major factor hindering the market growth during the forecast period. For instance, according to the data published by World Health Organization (WHO) in March 2018, in sub-Saharan Africa in 2010 and 2011, the direct cost of anti-venom alone ranged from US$ 55 to US$ 640 for an effective treatment, using recommended doses, with the average cost being US$ 124.7. Such high prices are not easily affordable by population in emerging economies.
Key players operating in the anti-venom market include BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., and Rare Disease Therapeutics Inc.